Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,452 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03924895 | Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) | active not recruiting | Phase 3 | 595 | Merck Sharp & Dohme LLCINDUSTRY | 28 | Jun 30, 2026 | clinicaltrials |
| NCT06135415 | A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis(TirbAKare) | completed | Phase 3 | 280 | Almirall, S.A. |
| 5 |
| Jun 30, 2026 |
| clinicaltrials |
| NCT06246149 | Adjuvant Tebentafusp in High Risk Ocular Melanoma(ATOM) | recruiting | Phase 3 | 290 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jun 30, 2026 | clinicaltrials |
| NCT03173248 | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation(AGILE) | active not recruiting | Phase 3 | 146 | Institut de Recherches Internationales ServierOTHER | 20 | Jun 29, 2026 | clinicaltrials |
| NCT02393859 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 3 | 111 | AmgenINDUSTRY | 24 | Jun 26, 2026 | clinicaltrials |
| NCT03088540 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 712 | Regeneron PharmaceuticalsINDUSTRY | 24 | Jun 25, 2026 | clinicaltrials |
| NCT03872401 | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke(VESALIUS-CV) | completed | Phase 3 | 12,301 | AmgenINDUSTRY | 33 | Jun 25, 2026 | clinicaltrials |
| NCT04529772 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)(ESCALADE) | active not recruiting | Phase 3 | 611 | Acerta Pharma BVINDUSTRY | 23 | Jun 25, 2026 | clinicaltrials |
| NCT06216301 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC(LUNAR-2) | recruiting | Phase 3 | 734 | NovoCure GmbHINDUSTRY | 16 | Jun 25, 2026 | clinicaltrials |
| NCT05024773 | Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) | active not recruiting | Phase 3 | 130 | Fidia Farmaceutici s.p.a.INDUSTRY | 6 | Jun 23, 2026 | clinicaltrials |
| NCT05555732 | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | active not recruiting | Phase 3 | 1,170 | Daiichi SankyoINDUSTRY | 29 | Jun 23, 2026 | clinicaltrials |
| NCT05059522 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | active not recruiting | Phase 3 | 77 | PfizerINDUSTRY | 19 | Jun 22, 2026 | clinicaltrials |
| NCT05696626 | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation(ELAINEIII) | recruiting | Phase 3 | 600 | LeonaBioINDUSTRY | 17 | Jun 22, 2026 | clinicaltrials |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation(IMbrave050) | completed | Phase 3 | 668 | Hoffmann-La RocheINDUSTRY | 26 | Jun 18, 2026 | clinicaltrials |
| NCT04475939 | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer(ZEAL-1L) | completed | Phase 3 | 666 | GlaxoSmithKlineINDUSTRY | 27 | Jun 18, 2026 | clinicaltrials |
| NCT05221840 | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC-9) | active not recruiting | Phase 3 | 1,051 | AstraZenecaINDUSTRY | 20 | Jun 18, 2026 | clinicaltrials |
| NCT06088290 | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)(SaLuDo) | active not recruiting | Phase 3 | 469 | PharmaMarINDUSTRY | 12 | Jun 18, 2026 | clinicaltrials |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | recruiting | Phase 3 | 400 | Ascentage Pharma Group Inc.INDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | recruiting | Phase 3 | 180 | Vor BiopharmaINDUSTRY | 14 | Jun 18, 2026 | clinicaltrials |
| NCT07215585 | AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL(SOUNDTRACK-D2) | recruiting | Phase 3 | 420 | AstraZenecaINDUSTRY | 11 | Jun 18, 2026 | clinicaltrials |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects(CANOPY-1) | terminated | Phase 3 | 673 | Novartis PharmaceuticalsINDUSTRY | 41 | Jun 17, 2026 | clinicaltrials |
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | active not recruiting | Phase 3 | 281 | Alexion Pharmaceuticals, Inc.INDUSTRY | 19 | Jun 17, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | active not recruiting | Phase 3 | 260 | Alexion Pharmaceuticals, Inc.INDUSTRY | 22 | Jun 17, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT05271162 | Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines(EMPACT) | active not recruiting | Phase 3 | 220 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02513394 | PALbociclib CoLlaborative Adjuvant Study(PALLAS) | active not recruiting | Phase 3 | 5,796 | Alliance Foundation Trials, LLC.OTHER | 21 | Jun 15, 2026 | clinicaltrials |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC(KANGUROO) | recruiting | Phase 2 / Phase 3 | 71 | Urovant Sciences GmbHINDUSTRY | 16 | Jun 15, 2026 | clinicaltrials |
| NCT04421963 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib(ROSY-O) | active not recruiting | Phase 3 | 185 | AstraZenecaINDUSTRY | 23 | Jun 12, 2026 | clinicaltrials |
| NCT04484623 | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma(DREAMM 8) | active not recruiting | Phase 3 | 302 | GlaxoSmithKlineINDUSTRY | 18 | Jun 12, 2026 | clinicaltrials |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy(Viale-a) | active not recruiting | Phase 3 | 443 | AbbVieINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT03003962 | Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | active not recruiting | Phase 3 | 669 | AstraZenecaINDUSTRY | 12 | Jun 11, 2026 | clinicaltrials |
| NCT03194893 | A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer | completed | Phase 3 | 50 | Hoffmann-La RocheINDUSTRY | 9 | Jun 11, 2026 | clinicaltrials |
| NCT04607421 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 841 | PfizerINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT06267001 | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy(SKYSCRAPER-15) | terminated | Phase 3 | 56 | Hoffmann-La RocheINDUSTRY | 11 | Jun 10, 2026 | clinicaltrials |
| NCT03301220 | A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma | completed | Phase 3 | 390 | Janssen Research & Development, LLCINDUSTRY | 24 | Jun 8, 2026 | clinicaltrials |
| NCT04720157 | An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)(PSMAddition) | active not recruiting | Phase 3 | 1,140 | Novartis PharmaceuticalsINDUSTRY | 19 | Jun 8, 2026 | clinicaltrials |
| NCT04871282 | A Study of AL102 in Patients With Progressing Desmoid Tumors(RINGSIDE) | active not recruiting | Phase 2 / Phase 3 | 198 | Immunome, Inc.INDUSTRY | 11 | Jun 8, 2026 | clinicaltrials |
| NCT04960709 | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin(VOLGA) | active not recruiting | Phase 3 | 712 | AstraZenecaINDUSTRY | 25 | Jun 4, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT04164199 | Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | completed | Phase 3 | 404 | BeOne MedicinesINDUSTRY | 13 | Jun 3, 2026 | clinicaltrials |
| NCT04513925 | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)(SKYSCRAPER-03) | completed | Phase 3 | 829 | Hoffmann-La RocheINDUSTRY | 26 | Jun 3, 2026 | clinicaltrials |
| NCT04619797 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(SKYSCRAPER-06) | completed | Phase 2 / Phase 3 | 542 | Hoffmann-La RocheINDUSTRY | 21 | Jun 3, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT03652064 | A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | completed | Phase 3 | 395 | Janssen Research & Development, LLCINDUSTRY | 13 | Jun 2, 2026 | clinicaltrials |
| NCT05445778 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer(GLORIOSA) | active not recruiting | Phase 3 | 520 | AbbVieINDUSTRY | 22 | Jun 2, 2026 | clinicaltrials |
| NCT02972840 | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | active not recruiting | Phase 3 | 635 | Acerta Pharma BVINDUSTRY | 27 | Jun 1, 2026 | clinicaltrials |
| NCT02075840 | A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants(ALEX) | completed | Phase 3 | 303 | Hoffmann-La RocheINDUSTRY | 29 | May 29, 2026 | clinicaltrials |
| NCT04223856 | Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer(EV-302) | active not recruiting | Phase 3 | 886 | Astellas Pharma Global Development, Inc.INDUSTRY | 25 | May 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials